<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39367485</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>05</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>07</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2047-783X</ISSN><JournalIssue CitedMedium="Internet"><Volume>29</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>04</Day></PubDate></JournalIssue><Title>European journal of medical research</Title><ISOAbbreviation>Eur J Med Res</ISOAbbreviation></Journal><ArticleTitle>Does early combination vs. Monotherapy improve clinical outcomes of clinically extremely vulnerable patients with COVID-19? Results from a retrospective propensity-weighted analysis.</ArticleTitle><Pagination><StartPage>484</StartPage><MedlinePgn>484</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">484</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s40001-024-02062-5</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The potential efficacy of early combination therapy, based on an antiviral plus a monoclonal antibody, for COVID-19 in severely immunocompromised patients is matter of debate.</AbstractText><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">Our aim was to describe the impact on clinical outcomes of COVID-19 treatments in severely immunocompromised individuals, evaluating differences between a combination and a monotherapy.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We included severely immunocompromised outpatients with mild-to-moderate COVID-19 who received an early treatment (either monotherapy with nirmatrelvir/ritonavir or remdesivir or the combination of an antiviral plus sotrovimab). We then assessed differences between the two treatment strategies on three main outcomes (30-day mortality, access to emergency department, hospitalization), separately and as a composite by using a propensity score weighted (PSW) approach.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Eighty one severely immunocompromised patients were included, 39 receiving early combination therapy and 42 receiving monotherapy. No significant difference was observed in the 30-day mortality rate and hospitalization rate between subjects in the two groups, while access to the emergency department following treatment administration was significantly higher in people who received a combination therapy. After applying the PSW, it was observed that combination therapy impacted favourably on the composite outcome, in a statistically significant fashion. In addition, PSW approach for mortality showed that age was the only significant factor influencing the death as stand-alone outcome.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Early combination therapy showed a favourable impact on a composite outcome (including mortality, hospitalizations and access to emergency department) in severely immunocompromised hosts who were all vaccinated. However, further studies are needed to support our results.</AbstractText><CopyrightInformation>© 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Maria</LastName><ForeName>Mazzitelli</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-0263-0703</Identifier><AffiliationInfo><Affiliation>Infectious and Tropical Diseases Unit, Padua University Hospital, 35128, Padua, Italy. m.mazzitelli88@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Maraolo</LastName><ForeName>Alberto Enrico</ForeName><Initials>AE</Initials><AffiliationInfo><Affiliation>Section of Infectious Diseases, Department of Clinical Medicine and Surgery, University of Naples "Federico II", 80131, Naples, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cozzolino</LastName><ForeName>Claudia</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Cardiac, Thoracic, Vascular Sciences, and Public Health, University of Padua, 35131, Padua, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sasset</LastName><ForeName>Lolita</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Infectious and Tropical Diseases Unit, Padua University Hospital, 35128, Padua, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ferrari</LastName><ForeName>Anna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Infectious and Tropical Diseases Unit, Padua University Hospital, 35128, Padua, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Basso</LastName><ForeName>Monica</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Infectious and Tropical Diseases Unit, Padua University Hospital, 35128, Padua, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vania</LastName><ForeName>Eleonora</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Infectious and Tropical Diseases Unit, Padua University Hospital, 35128, Padua, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bonadiman</LastName><ForeName>Nicola</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Infectious and Tropical Diseases Unit, Padua University Hospital, 35128, Padua, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scaglione</LastName><ForeName>Vincenzo</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Infectious and Tropical Diseases Unit, Padua University Hospital, 35128, Padua, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cattelan</LastName><ForeName>Anna Maria</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Infectious and Tropical Diseases Unit, Padua University Hospital, 35128, Padua, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Eur J Med Res</MedlineTA><NlmUniqueID>9517857</NlmUniqueID><ISSNLinking>0949-2321</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>3QKI37EEHE</RegistryNumber><NameOfSubstance UI="C000606551">remdesivir</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>O3J8G9O825</RegistryNumber><NameOfSubstance UI="D019438">Ritonavir</NameOfSubstance></Chemical><Chemical><RegistryNumber>415SHH325A</RegistryNumber><NameOfSubstance UI="D000249">Adenosine Monophosphate</NameOfSubstance></Chemical><Chemical><RegistryNumber>OF5P57N2ZX</RegistryNumber><NameOfSubstance UI="D000409">Alanine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000093485" MajorTopicYN="Y">COVID-19 Drug Treatment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004359" MajorTopicYN="Y">Drug Therapy, Combination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="Y">Antiviral Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057216" MajorTopicYN="Y">Propensity Score</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019438" MajorTopicYN="Y">Ritonavir</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000249" MajorTopicYN="N">Adenosine Monophosphate</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="N">analogs &amp; derivatives</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000409" MajorTopicYN="N">Alanine</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="N">analogs &amp; derivatives</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016867" MajorTopicYN="N">Immunocompromised Host</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006760" MajorTopicYN="N">Hospitalization</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Combined treatment</Keyword><Keyword MajorTopicYN="N">Early treatment</Keyword><Keyword MajorTopicYN="N">Monotherapy</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">Severe immunocompromised patients</Keyword></KeywordList><CoiStatement>M.M. and A.C. received a research grant from Gilead Sciences, speakers’ honoraria from ViiV Healthcare, Gilead Sciences, and Merck Sharp &amp; Dohme, and advisory board fees from ViiV Healthcare. V.S. received speakers’ honoraria from Angelini. All the other authors do not have any conflicts of interest to disclose. The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>8</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>5</Day><Hour>11</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>5</Day><Hour>11</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>4</Day><Hour>23</Hour><Minute>47</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>4</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39367485</ArticleId><ArticleId IdType="pmc">PMC11451216</ArticleId><ArticleId IdType="doi">10.1186/s40001-024-02062-5</ArticleId><ArticleId IdType="pii">10.1186/s40001-024-02062-5</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Razonable RR. Protecting the vulnerable: addressing the COVID-19 care needs of people with compromised immunity. Front Immunol. 2024;15:1397040. 10.3389/fimmu.2024.1397040.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11096526</ArticleId><ArticleId IdType="pubmed">38756784</ArticleId></ArticleIdList></Reference><Reference><Citation>Feys S, Lagrou K, Lauwers HM, Haenen K, Jacobs C, Brusselmans M, et al. High burden of COVID-19-associated pulmonary aspergillosis in severely immunocompromised patients requiring mechanical ventilation. Clin Infect Dis. 2024;78(2):361–70. 10.1093/cid/ciad546.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10874259</ArticleId><ArticleId IdType="pubmed">37691392</ArticleId></ArticleIdList></Reference><Reference><Citation>DeWolf S, Laracy JC, Perales MA, Kamboj M, van den Brink MRM, Vardhana S. SARS-CoV-2 in immunocompromised individuals. Immunity. 2022;55(10):1779–98. 10.1016/j.immuni.2022.09.006.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9468314</ArticleId><ArticleId IdType="pubmed">36182669</ArticleId></ArticleIdList></Reference><Reference><Citation>De Vito A, Saderi L, Colpani A, Puci MV, Zauli B, Fiore V, et al. New score to predict COVID-19 progression in vaccine and early treatment era: the COVID-19 Sardinian Progression Score (CSPS). Eur J Med Res. 2024;29(1):123. 10.1186/s40001-024-01718-6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10868088</ArticleId><ArticleId IdType="pubmed">38360688</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan JF, Yuan S, Chu H, Sridhar S, Yuen KY. COVID-19 drug discovery and treatment options. Nat Rev Microbiol. 2024. 10.1038/s41579-024-01036-y.</Citation><ArticleIdList><ArticleId IdType="pubmed">38622352</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Castelnuovo A, Costanzo S, Antinori A, Berselli N, Blandi L, Bonaccio M, et al. Lopinavir/ritonavir and darunavir/cobicistat in hospitalized COVID-19 patients: findings from the multicenter Italian CORIST study. Front Med (Lausanne). 2021;8:639970. 10.3389/fmed.2021.639970.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8221239</ArticleId><ArticleId IdType="pubmed">34179035</ArticleId></ArticleIdList></Reference><Reference><Citation>De Vito A, Moi G, Saderi L, Puci MV, Colpani A, Firino L, et al. Vaccination and antiviral treatment reduce the time to negative SARS-CoV-2 swab: a real-life study. Viruses. 2023;15(11):2180. 10.3390/v15112180.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10675806</ArticleId><ArticleId IdType="pubmed">38005858</ArticleId></ArticleIdList></Reference><Reference><Citation>Spaccarotella C, Mazzitelli M, Migliarino S, Curcio A, De Rosa S, Torti C, et al. Therapy with RAS inhibitors during the COVID-19 pandemic. J Cardiovasc Med (Hagerstown). 2021;22(5):329–34. 10.2459/JCM.0000000000001160.</Citation><ArticleIdList><ArticleId IdType="pubmed">33795584</ArticleId></ArticleIdList></Reference><Reference><Citation>Mengato D, Mazzitelli M, Francavilla A, Bettio M, Sasset L, Presa N, et al. Changing patterns and clinical outcomes of hospitalized patients with COVID-19 severe pneumonia treated with remdesivir according to vaccination status: results from a real-world retrospective study. Clin Exp Med. 2023;23(6):2749–56. 10.1007/s10238-023-01036-x.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10037380</ArticleId><ArticleId IdType="pubmed">36961678</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazzitelli M, Mengato D, Sasset L, Ferrari A, Gardin S, Scaglione V, et al. Molnupiravir and nirmatrelvir/ritonavir: tolerability, safety, and adherence in a retrospective cohort study. Viruses. 2023;15(2):384. 10.3390/v15020384.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9962206</ArticleId><ArticleId IdType="pubmed">36851598</ArticleId></ArticleIdList></Reference><Reference><Citation>Dioverti V, Salto-Alejandre S, Haidar G. Immunocompromised patients with protracted COVID-19: a Review of “Long Persisters.” Curr Transplant Rep. 2022;9(4):209–18. 10.1007/s40472-022-00385-y.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9660019</ArticleId><ArticleId IdType="pubmed">36407883</ArticleId></ArticleIdList></Reference><Reference><Citation>Gentile I, Foggia M, Silvitelli M, Sardanelli A, Cattaneo L, Viceconte G. Optimizing COVID-19 treatment in immunocompromised patients: early combination therapy with remdesivir, nirmatrelvir/ritonavir and sotrovimab. Virol J. 2023;20(1):301. 10.1186/s12985-023-02269-8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10724917</ArticleId><ArticleId IdType="pubmed">38102675</ArticleId></ArticleIdList></Reference><Reference><Citation>Focosi D, Franchini M, Maggi F, Shoham S. COVID-19 therapeutics. Clin Microbiol Rev. 2024;2024:e0011923. 10.1128/cmr.00119-23.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11237566</ArticleId><ArticleId IdType="pubmed">38771027</ArticleId></ArticleIdList></Reference><Reference><Citation>Torti C, Olimpieri PP, Bonfanti P, Tascini C, Celant S, Tacconi D, et al. Real-life comparison of mortality in patients with SARS-CoV-2 infection at risk for clinical progression treated with molnupiravir or nirmatrelvir plus ritonavir during the Omicron era in Italy: a nationwide, cohort study. Lancet Reg Health Eur. 2023;31: 100684. 10.1016/j.lanepe.2023.100684.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10398591</ArticleId><ArticleId IdType="pubmed">37547273</ArticleId></ArticleIdList></Reference><Reference><Citation>Eastman RT, Roth JS, Brimacombe KR, Simeonov A, Shen M, Patnaik S, et al. Remdesivir: a review of its discovery and development leading to emergency use authorization for treatment of COVID-19. ACS Cent Sci. 2020;6(5):672–83. 10.1021/acscentsci.0c00489.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7202249</ArticleId><ArticleId IdType="pubmed">32483554</ArticleId></ArticleIdList></Reference><Reference><Citation>Godwin PO, Polsonetti B, Caron MF, Oppelt TF. Remdesivir for the treatment of COVID-19: a narrative review. Infect Dis Ther. 2024;13(1):1–19. 10.1007/s40121-023-00900-3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10828241</ArticleId><ArticleId IdType="pubmed">38193988</ArticleId></ArticleIdList></Reference><Reference><Citation>Mozaffari E, Chandak A, Gottlieb RL, Chima-Melton C, Read SH, Jiang H, et al. Remdesivir reduced mortality in immunocompromised patients hospitalized for COVID-19 across variant waves: findings from routine clinical practice. Clin Infect Dis. 2023;77(12):1626–34. 10.1093/cid/ciad460.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10724457</ArticleId><ArticleId IdType="pubmed">37556727</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazzitelli M, Trunfio M, Sasset L, Scaglione V, Ferrari A, Mengato D, et al. Risk of hospitalization and sequelae in patients with COVID-19 treated with 3-day early remdesivir vs. controls in the vaccine and Omicron era: a real-life cohort study. J Med Virol. 2023;95(3):e28660. 10.1002/jmv.28660.</Citation><ArticleIdList><ArticleId IdType="pubmed">36905216</ArticleId></ArticleIdList></Reference><Reference><Citation>Caso JM, Fernandez-Ruiz M, Lopez-Medrano F, Caro-Teller JM, Lizasoain M, San-Juan R, et al. Nirmatrelvir/ritonavir for the treatment of immunocompromised adult patients with early-stage symptomatic COVID-19: a real-life experience. J Med Virol. 2023;95(9): e29082. 10.1002/jmv.29082.</Citation><ArticleIdList><ArticleId IdType="pubmed">37671852</ArticleId></ArticleIdList></Reference><Reference><Citation>Basoulis D, Tsakanikas A, Gkoufa A, Bitsani A, Karamanakos G, Mastrogianni E, et al. Effectiveness of oral nirmatrelvir/ritonavir vs. intravenous three-day remdesivir in preventing progression to severe COVID-19: a single-center, prospective, comparative, real-life study. Viruses. 2023;15(7):1515. 10.3390/v15071515.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10383489</ArticleId><ArticleId IdType="pubmed">37515201</ArticleId></ArticleIdList></Reference><Reference><Citation>Bai F, Beringheli T, Vitaletti V, Santoro A, Mola F, Copes A, et al. Clinical outcome and 7-day virological clearance in high-risk patients with mild-moderate COVID-19 treated with molnupiravir, nirmatrelvir/ritonavir, or remdesivir. Infect Dis Ther. 2024;13(7):1589–605. 10.1007/s40121-024-00994-3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11219607</ArticleId><ArticleId IdType="pubmed">38829439</ArticleId></ArticleIdList></Reference><Reference><Citation>Gottlieb RL, Nirula A, Chen P, Boscia J, Heller B, Morris J, et al. Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: a randomized clinical trial. JAMA. 2021;325(7):632–44. 10.1001/jama.2021.0202.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7821080</ArticleId><ArticleId IdType="pubmed">33475701</ArticleId></ArticleIdList></Reference><Reference><Citation>Weinreich DM, Sivapalasingam S, Norton T, Ali S, Gao H, Bhore R, et al. REGEN-COV antibody combination and outcomes in outpatients with Covid-19. N Engl J Med. 2021;385(23): e81. 10.1056/NEJMoa2108163.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8522800</ArticleId><ArticleId IdType="pubmed">34587383</ArticleId></ArticleIdList></Reference><Reference><Citation>Iketani S, Liu L, Guo Y, Liu L, Chan JF, Huang Y, et al. Antibody evasion properties of SARS-CoV-2 Omicron sublineages. Nature. 2022;604(7906):553–6. 10.1038/s41586-022-04594-4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9021018</ArticleId><ArticleId IdType="pubmed">35240676</ArticleId></ArticleIdList></Reference><Reference><Citation>Mikulska M, Sepulcri C, Dentone C, Magne F, Balletto E, Baldi F, et al. Triple combination therapy with 2 antivirals and monoclonal antibodies for persistent or relapsed severe acute respiratory syndrome coronavirus 2 infection in immunocompromised patients. Clin Infect Dis. 2023;77(2):280–6. 10.1093/cid/ciad181.</Citation><ArticleIdList><ArticleId IdType="pubmed">36976301</ArticleId></ArticleIdList></Reference><Reference><Citation>Gilbert PB, Montefiori DC, McDermott AB, Fong Y, Benkeser D, Deng W, et al. Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial. Science. 2022;375(6576):43–50. 10.1126/science.abm3425.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9017870</ArticleId><ArticleId IdType="pubmed">34812653</ArticleId></ArticleIdList></Reference><Reference><Citation>Antinori A, Bausch-Jurken M. The burden of COVID-19 in the immunocompromised patient: implications for vaccination and needs for the future. J Infect Dis. 2023;228(Suppl 1):S4–12. 10.1093/infdis/jiad181.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10401620</ArticleId><ArticleId IdType="pubmed">37539764</ArticleId></ArticleIdList></Reference><Reference><Citation>Update to living WHO guideline on drugs for covid-19. BMJ. 2023;383:2622. 10.1136/bmj.p2622.</Citation><ArticleIdList><ArticleId IdType="pubmed">37945036</ArticleId></ArticleIdList></Reference><Reference><Citation>Cepeda MS, Boston R, Farrar JT, Strom BL. Comparison of logistic regression versus propensity score when the number of events is low and there are multiple confounders. Am J Epidemiol. 2003;158(3):280–7. 10.1093/aje/kwg115.</Citation><ArticleIdList><ArticleId IdType="pubmed">12882951</ArticleId></ArticleIdList></Reference><Reference><Citation>Chesnaye NC, Stel VS, Tripepi G, Dekker FW, Fu EL, Zoccali C, et al. An introduction to inverse probability of treatment weighting in observational research. Clin Kidney J. 2022;15(1):14–20. 10.1093/ckj/sfab158.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8757413</ArticleId><ArticleId IdType="pubmed">35035932</ArticleId></ArticleIdList></Reference><Reference><Citation>McCaffrey DF, Ridgeway G, Morral AR. Propensity score estimation with boosted regression for evaluating causal effects in observational studies. Psychol Methods. 2004;9(4):403–25. 10.1037/1082-989X.9.4.403.</Citation><ArticleIdList><ArticleId IdType="pubmed">15598095</ArticleId></ArticleIdList></Reference><Reference><Citation>Brookhart MA, Schneeweiss S, Rothman KJ, Glynn RJ, Avorn J, Sturmer T. Variable selection for propensity score models. Am J Epidemiol. 2006;163(12):1149–56. 10.1093/aje/kwj149.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1513192</ArticleId><ArticleId IdType="pubmed">16624967</ArticleId></ArticleIdList></Reference><Reference><Citation>Garrido MM. Propensity scores: a practical method for assessing treatment effects in pain and symptom management research. J Pain Symptom Manage. 2014;48(4):711–8. 10.1016/j.jpainsymman.2014.05.014.</Citation><ArticleIdList><ArticleId IdType="pubmed">24937162</ArticleId></ArticleIdList></Reference><Reference><Citation>Orth HM, Flasshove C, Berger M, Hattenhauer T, Biederbick KD, Mispelbaum R, et al. Early combination therapy of COVID-19 in high-risk patients. Infection. 2024;52(3):877–89. 10.1007/s15010-023-02125-5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11142969</ArticleId><ArticleId IdType="pubmed">38017344</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhimraj A, Morgan RL, Shumaker AH, Baden L, Cheng VCC, Edwards KM, et al. Infectious diseases society of America Guidelines on the treatment and management of patients with COVID-19. Clin Infect Dis. 2022. 10.1093/cid/ciac724.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7197612</ArticleId><ArticleId IdType="pubmed">32338708</ArticleId></ArticleIdList></Reference><Reference><Citation>Scaglione V, Rotundo S, Marascio N, De Marco C, Lionello R, Veneziano C, et al. Publisher Correction: Lessons learned and implications of early therapies for coronavirus disease in a territorial service centre in the Calabria region: a retrospective study. BMC Infect Dis. 2022;22(1):883. 10.1186/s12879-022-07871-9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9700875</ArticleId><ArticleId IdType="pubmed">36434528</ArticleId></ArticleIdList></Reference><Reference><Citation>Rotundo S, Berardelli L, Gulli S, La Gamba V, Lionello R, Russo A, et al. Early initiation of combined therapy in severely immunocompromised patients with COVID-19: a retrospective cohort study. BMC Infect Dis. 2024;24(1):564. 10.1186/s12879-024-09466-y.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11155142</ArticleId><ArticleId IdType="pubmed">38844861</ArticleId></ArticleIdList></Reference><Reference><Citation>Evans RA, Dube S, Lu Y, Yates M, Arnetorp S, Barnes E, et al. Impact of COVID-19 on immunocompromised populations during the Omicron era: insights from the observational population-based INFORM study. Lancet Reg Health Eur. 2023;35: 100747. 10.1016/j.lanepe.2023.100747.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10730312</ArticleId><ArticleId IdType="pubmed">38115964</ArticleId></ArticleIdList></Reference><Reference><Citation>Boeckh M, Pergam SA, Limaye AP, Englund J, Corey L, Hill JA. How immunocompromised hosts were left behind in the quest to control the Covid-19 Pandemic. Clin Infect Dis. 2024. 10.1093/cid/ciae308.</Citation><ArticleIdList><ArticleId IdType="pubmed">38825885</ArticleId></ArticleIdList></Reference><Reference><Citation>Machkovech HM, Hahn AM, Garonzik Wang J, Grubaugh ND, Halfmann PJ, Johnson MC, et al. Persistent SARS-CoV-2 infection: significance and implications. Lancet Infect Dis. 2024. 10.1016/S1473-3099(23)00815-0.</Citation><ArticleIdList><ArticleId IdType="pubmed">38340735</ArticleId></ArticleIdList></Reference><Reference><Citation>Meijer SE, Paran Y, Belkin A, Brosh-Nissimov T. ’Persistent COVID-19 in immunocompromised patients—Israeli society of infectious diseases consensus statement on diagnosis and management’—Author’s reply. Clin Microbiol Infect. 2024. 10.1016/j.cmi.2024.05.022.</Citation><ArticleIdList><ArticleId IdType="pubmed">38642895</ArticleId></ArticleIdList></Reference><Reference><Citation>Maraolo AE, Moriello NS, Gentile I. Re: Persistent COVID-19 in immunocompromised patients—Israeli Society of Infectious Diseases consensus statement on diagnosis and management by Meijer et al. Clin Microbiol Infect. 2024. 10.1016/j.cmi.2024.05.011.</Citation><ArticleIdList><ArticleId IdType="pubmed">38782259</ArticleId></ArticleIdList></Reference><Reference><Citation>Focosi D, Maggi F, D’Abramo A, Nicastri E, Sullivan DJ. Antiviral combination therapies for persistent COVID-19 in immunocompromised patients. Int J Infect Dis. 2023;137:55–9. 10.1016/j.ijid.2023.09.021.</Citation><ArticleIdList><ArticleId IdType="pubmed">37778409</ArticleId></ArticleIdList></Reference><Reference><Citation>Sundararaj Stanleyraj J, Sethuraman N, Gupta R, Thiruvoth S, Gupta M, Ryo A. Treating COVID-19: are we missing out the window of opportunity? J Antimicrob Chemother. 2021;76(2):283–5. 10.1093/jac/dkaa442.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7665528</ArticleId><ArticleId IdType="pubmed">33099620</ArticleId></ArticleIdList></Reference><Reference><Citation>Cevik M, Tate M, Lloyd O, Maraolo AE, Schafers J, Ho A. SARS-CoV-2, SARS-CoV, and MERS-CoV viral load dynamics, duration of viral shedding, and infectiousness: a systematic review and meta-analysis. Lancet Microbe. 2021;2(1):e13–22. 10.1016/S2666-5247(20)30172-5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7837230</ArticleId><ArticleId IdType="pubmed">33521734</ArticleId></ArticleIdList></Reference><Reference><Citation>Focosi D, Casadevall A, Franchini M, Maggi F. Sotrovimab: a review of its efficacy against SARS-CoV-2 variants. Viruses. 2024;16(2):217. 10.3390/v16020217.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10891757</ArticleId><ArticleId IdType="pubmed">38399991</ArticleId></ArticleIdList></Reference><Reference><Citation>De Vito A, Colpani A, Poliseno M, Diella L, Ieva FRP, Belati A, et al. What is the efficacy of sotrovimab in reducing disease progression and death in people with COVID-19 during the Omicron Era? Answers from a real-life study. Viruses. 2023;15(8):1757. 10.3390/v15081757.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10458484</ArticleId><ArticleId IdType="pubmed">37632099</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith DJ, Lambrou A, Patel P. SARS-CoV-2 rebound with and without use of COVID-19 oral antivirals. MMWR Morb Mortal Wkly Rep. 2023;72(51):1357–64. 10.15585/mmwr.mm7251a1.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10754268</ArticleId><ArticleId IdType="pubmed">38127665</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang SW, Kim JW, Kim JY, Lim SY, Jang CY, Chang E, et al. Virological characteristics and the rapid antigen test as deisolation criteria in immunocompromised patients with COVID-19: a prospective cohort study. J Med Virol. 2023;95(11): e29228. 10.1002/jmv.29228.</Citation><ArticleIdList><ArticleId IdType="pubmed">38009999</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>